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ABSTRACT 
 
Bronchiectasis is a condition of increasing incidence and prevalence around the world. 
Many different diseases have been associated with bronchiectasis, and their treatment can differ 
widely. Recent guidelines have helped to approach aetiological diagnosis but it is still a complex 
process. Identifying the cause of the bronchiectasis may determine a change in the treatment of a 
large group of subjects. That is one of the main reasons why the aetiological diagnosis is crucial 
in the proper management of bronchiectasis patients.  
Postinfectious bronchiectasis is the most frequent entity among different studies, but a 
high percentage of cases still remain without a clear aetiology. Bronchiectasis related to allergic 
bronchopulmonary aspergillosis (ABPA), immunodeficiencies with antibody production 
deficiency, primary ciliary dyskinesia, cystic fibrosis and alpha-1-antitrypsin deficiency, among 
others, require a specific management that may improve quality of life and prognosis in a large 
group of individuals. 
Therefore, the aim of this article is to review the main bronchiectasis related diseases and 
to simplify the aetiological diagnosis, in order to improve the management of bronchiectasis 
patients, especially in those where a specific treatment is available. 
 
 
 
 
 
1. INTRODUCTION 
Non-cystic fibrosis (CF) Bronchiectasis (henceforth referred as bronchiectasis) is a 
progressive disease characterized by a permanent dilatation of bronchi, retention of mucus and 
ciliary clearance impairment. These changes are a result of very diverse pulmonary or systemic 
diseases, which can influence the course of the disease. Therefore, aetiological investigation is 
one of the key aspects in the management of patients with bronchiectasis [1,2]. 
Causes of bronchiectasis are many and varied, making the aetiological diagnosis process 
difficult. The most common causes are previous lung infections such as pneumonia or pulmonary 
tuberculosis, primary and secondary immunodeficiencies, CF, abnormal ciliary function, allergic 
bronchopulmonary aspergillosis (ABPA) and connective tissue diseases. Bronchiectasis has also 
been associated with other chronic respiratory diseases such as asthma and chronic obstructive 
pulmonary disease (COPD)[3]. In addition, recent studies focusing on the aetiology of 
bronchiectasis has revealed a high percentage of patients with no identifiable cause despite 
undergoing extensive studies for this purpose that are considered idiopathic [4–7]. 
The treatment of diseases associated with bronchiectasis can differ widely among them. 
Some bronchiectasis aetiologies can determine a change in patient management such as initiating 
a specific treatment, closer follow-up, genetic testing for relatives or modifying risk factors [6,7]. 
Therefore, it is important to identify the aetiological cause of the bronchiectasis for a proper 
management. Current guidelines recommendations for the aetiolology of bronchiectasis include 
an extensive laboratory and instrumental workup, as well as lung function tests and 
microbiological evaluation [1,2]. The aim of this article is to review the main diseases associated 
with bronchiectasis in order to simplify the process of the aetiological diagnosis and therefore to 
help improving patient management when a treatable or modifiable cause is identified. 
2. AETIOLOGIES 
The causes most frequently identified in patients with bronchiectasis are summarized in 
Table 1. The entities that have been associated with the development of bronchiectasis are 
numerous, and their prevalence varies depending on the population studied. Most studies 
directed to characterising patients with bronchiectasis to date have focused on specific 
populations in the UK, which can make it difficult to extrapolate the results to other countries 
and outside of highly specialised centres[4–6]. Recently, Lonni and colleagues conducted an 
analysis of 1,258 patients from seven cohorts in different countries included in the European 
Bronchiectasis Registry (EMBARC) in the study directed to the most extensive identification of 
aetiologies of bronchiectasis to date[7]. This study has shown that the cause of bronchiectasis 
was identified in approximately 60% of individuals. Among these, the most frequent were 
postinfectious (20%), COPD-related bronchiectasis (15%), connective tissue disease-related 
(10%), immunodeficiencies (5.8%) and asthma-related bronchiectasis (3.3%)[7]. Table 2 
summarizes the distribution of aetiologies most frequently identified in recent studies. 
 
 
 
 
 
 
 
 
Table 1. Aetiologies of bronchiectasis 
 
HIV: human immunodeficiency virus; COPD, chronic obstructive pulmonary disease 
Postinfectious  
Necrotising pneumonia 
Tuberculosis and non-tuberculosis mycobacterium  
Viruses (adenovirus, measles and other childhood infections) 
Immunodeficiencies  
* Primary: antibody deficiency, combined immunodeficiency, neutrophil dysfunction, Wiskott-Aldrich 
syndrome, among others 
* Secondary: HIV infection, haematological malignancies, chemotherapy, transplant 
Hypersensitivity  
Allergic bronchopulmonary aspergillosis 
Associated with lung diseases  
Asthma 
COPD 
Swyer-James Syndrome   
Diseases associated with connective tissue   
Rheumatoid Arthritis  
Sjögren Syndrome  
Other: Ankylosing spondylitis systemic sclerosis, systemic lupus erythematosus, ankylosing 
spondylitis, relapsing polychondritis, sarcoidosis, Marfan syndrome and Ehlers-Danlos syndrome  
Alteration of the mucociliary escalator  
Cystic fibrosis 
Primary ciliary dyskinesia 
Young’s syndrome 
Inflammatory bowel disease  
Ulcerative colitis 
Crohn's disease 
Inflammatory pneumonitis  
Aspiration and gastroesophageal reflux  
Toxic inhalation (drugs, gases, etc.) 
Congenital defects of the airway  
Tracheobronchomegaly (Mounier-Kuhn syndrome) 
Cartilage defects (Williams-Campbell syndrome) 
Pulmonary sequestration 
Tracheobronchomalacia 
Bronchial Obstruction  
* Intrinsic: scar stenosis, broncholithiasis, foreign body, tumour 
* Extrinsic: lymphadenopathy, tumour, aneurysm 
Others  
Alpha 1 antitrypsin deficiency 
Yellow nail syndrome 
Diffuse panbronchiolitis   
Idiopathic or unknown aetiology  
 Table 2. Distribution of the aetiologies of bronchiectasis in recent studies. 
 
 
Pasteur et 
al. (n=150) 
King et al. 
(n=103) 
Shoemark et al. 
(n=165) 
Anwar et al. 
(n=189) 
Lonni et al. 
(n=1258) 
Mean age (SD) 52,7 (15,2) 56 (14) 49 (16) 66,1 (11,5) 67 (58-75)* 
Gender (% M/F) 38/62 37/63 35/65 49/51 40/60 
Idiopathic (%) 53 74 26 43 40 
Postinfectious (%) 29 10 32 24 20 
Immunodeficiencies (%) 8 9 7 2 6 
ABPA (%) 7 4 8 4 5 
Connective tissue 
diseases (%) 
3 2 2 5 10 
COPD (%) - - - 12 15 
Asthma (%) - - - 3 3 
Inflammatory intestinal 
disease (%) 
1 - 3 2 2 
Cystic Fibrosis (%) 3 0 1 <1 0 
Ciliary dysfunction (%) 2 1 10 1 2 
AAT Deficiency (%) 0 0 0 1 <1 
Aspiration / GER (%) 4 0 1 1 <1 
Panbronchiolitis (%) <1 0 2 0 0 
Young’s Syndrome (%) 3 1 3 <1 0 
Yellow nail Syndrome 
(%) 
- - 2 - <1 
Congenital defect of the 
airway (%) 
<1 0 - - <1 
Pink’s disease (%) <1 - - <1 <1 
Other (%) - - 
Mycobacteria 
Infection: 2 
- 
Bronchial 
obstruction: 
<1 
* Data presented as median (interquartile range).  
SD: standard deviation; ABPA: allergic bronchopulmonary aspergillosis; COPD, chronic obstructive pulmonary 
disease; AAT: Alpha-1 antitrypsin; gastro-oesophageal reflux (GER) 
 2.1 Postinfectious  
This is the most frequently identified aetiology in most studies with a prevalence of 10-
32%[4–8]. This variability may be due to a higher prevalence of postinfectious aetiology in the 
most disadvantaged communities[9]. Infections that have been associated with the presence of 
bronchiectasis are bacterial or viral pneumonia, pulmonary tuberculosis and childhood infections 
such as measles and whooping cough[10–12]. 
Identifying this aetiology is often complicated because there may be biases in the data 
collection. Sometimes patients cannot recall previous infections or their severity, making it 
difficult to establish a temporal relationship between these infections and bronchiectasis. 
Shoemark et al. observed an important delay in the diagnostic of bronchiectasis. While the 
average age of onset of symptoms in these patients was 7 years, the average age for the 
diagnostic study of bronchiectasis was 49 years[5]. Therefore, in patients for whom the 
connection between the antecedent infection and the onset of symptoms of bronchiectasis is 
unclear, a more comprehensive aetiological study is recommended[2]. 
The incidence of bronchiectasis caused by non-tuberculosis mycobacterial (NTM) 
infections is a controversial point[11]. Although the presence of bronchiectasis predisposes 
colonization by opportunistic microorganisms such as NTM, it is also suggested that they play a 
role in the development of these bronchial disorders. Fujita et al. retrospectively evaluated 
resected lung specimens from 9 patients infected with Mycobacterium avium complex[13]. In all 
the cases they identified destruction of bronchial cartilage and of the smooth muscle layer as well 
as bronchial mucosa ulcerations and the presence of airway granulomas. Given these 
histopathological changes, the authors concluded that NTM infection could be a cause rather 
than a consequence of the appearance of bronchiectasis[13]. It has been suggested that certain 
host factors may increase the risk to develop pulmonary NTM infection [14]. Kartalija et al 
studied 103 patients with NTM infection and found that they were taller, had a significantly 
lower body mass index and body fat, and a higher prevalence of scoliosis and pectus excavatum 
than the 101 uninfected control subjects. Also, abnormal serum leptin and adiponectin levels 
were measured in NTM infected patients, resulting in suppressed blood IFN-γ and IL-10 levels 
[15]. Patients with M. avium infection classically are middle aged and elderly female patients 
with middle lobe bronchiectasis, who may have little cough (the so called, “Lady Windemere” 
syndrome), although disease associated with NTM should be considered in all patients.  
 
2.2 Immunodeficiencies 
Immunodeficiency is defined as the partial or complete failure to conduct an effective 
immune response to an infectious agent. It is classified as primary (or congenital) and secondary 
(or acquired). It comprises a heterogeneous group of conditions that can occur in both childhood 
and adulthood. In patients with primary or secondary immunodeficiencies, bronchiectasis may be 
the result of a state of persistent systemic and airway inflammation due to recurrent infectious 
episodes[16,17]. A study from Hurst et al. observed greater airway and systemic inflammation in 
patients with primary antibody deficiency compared to immunocompetent bronchiectasis 
controls. The severity of this systemic inflammatory response correlated with the rate of 
progression of lung disease and also to airway inflammation [17]. 
The presence of an immune deficiency in patients with bronchiectasis varies from 2-18% 
depending on the population studied[6,18]. The deficiency in the function or production of one 
or more kinds of immunoglobulines is the most common and clinically important manifestation 
of primary immunodeficiencies. Common variable immunodeficiency, X-linked 
agammaglobulinemia or immunoglobulin A deficiency are therefore common causes of 
bronchiectasis[4,19]. Other secondary immunodeficiences related to bronchiectasis are infection 
by the human immunodeficiency virus, immunosuppressive therapy or chemotherapy, and 
patients with haematological malignancies. 
There is often a history of recurrent respiratory (pneumonias, sinusitis) and non-
respiratory (otitis, meningitis, diarrhea) infections, but in many cases impaired immunity can be 
identified in apparently healthy subjects, which may produce a delay in diagnosis in these 
patients[20]. A history of frequent non-respiratory infections can give a clue to the presence of 
an underlying immunodeficiency. Treatment with immunoglobulin have demonstrated an 
improvement in lung function in patients with hypogammaglobulinemia[21]. Therefore, 
identifying these patients and initiating early specific treatment is essential in cases that require it 
to avoid the appearance of bronchiectasis and to slow down the progression of the disease. 
 
2.3 Chronic obstructive pulmonary disease (COPD) 
The presence of bronchiectasis associated with COPD is the aetiology that has generated 
most interest and controversy in recent years. It is due to the high prevalence of patients with 
COPD and to the undertaking of  more routine chest CT in these patients[22]. The prevalence of 
this bronchiectasis-COPD association differs depending on whether the studied population is a 
bronchiectasis series or a COPD series. Recent studies have found that about 12-15% of patients 
with bronchiectasis have a diagnosis of associated COPD[6,7]. However, it is believed that this 
association may be even greater when looking at COPD series. In a meta-analysis performed by 
Ni et al including six observational studies with 881 COPD patients, the mean prevalence of 
bronchiectasis was 54,3% [23]. A study in the UK showed that 29% of patients with COPD 
followed in primary care had morphological alterations of airway potentially classifiable as 
bronchiectasis[24]. A recent population study on 18,793 patients diagnosed with bronchiectasis 
also in the UK during 2004-2013 has shown that 36% of individuals had a diagnosis of 
COPD[25]. The prevalence of smoking history is also different depending on the studied 
population. In bronchiectasis series, 17-36% of patients were smokers or ex-smokers [5–
8,18,26], while in COPD studies almost all patients included had a smoking history, since this is 
one of the main causes related to this disease.  
The factors associated with the presence of bronchiectasis in COPD are severe airflow 
obstruction, isolation of potentially pathogenic microorganisms and at least one hospital 
admission due to an exacerbation of COPD in the last year[27]. In addition, the association of 
these diseases has shown a worse prognosis. Goeminne et al. observed that in patients with 
bronchiectasis and COPD mortality was almost three times higher than in patients with 
bronchiectasis without COPD (55% vs. 20%)[28]. Moreover, in patients with COPD and 
bronchiectasis on high resolution chest tomography, an increase in the number of exacerbations 
and hospitalizations as well as five-year mortality has been detected[29–31]. Martinez-Garcia 
and colleagues studied 201 patients diagnosed with COPD, of whom 57% had associated 
bronchiectasis. They noted that the coexistence of these entities is associated with a high risk of 
mortality from all causes in the group of patients with moderate to severe COPD[30]. 
These smaller studies may have overestimated the prevalence of bronchiectasis in COPD, 
as larger studies suggest a lower prevalence. In the ECLIPSE study (N=2161), an international 
multicentre COPD cohort, bronchiectasis was reported in only 2% of males with GOLD II 
COPD (<1% of females), increasing to 9% of females and 7% of males in very severe COPD 
(GOLD IV) [32].  
Whether the diagnosis is bronchiectasis with fixed airflow obstruction or COPD with 
suggestive anatomical abnormalities of bronchiectasis, this "overlap syndrome" has a significant 
impact on the management of both diseases and requires more studies to help understand its 
natural history and therefore to optimize the treatment given to date. 
 
2.4 Asthma 
The relationship between bronchiectasis and bronchial asthma is not clearly defined. 
Anwar et al. and Lonni et al. observed a prevalence of bronchiectasis associated with bronchial 
asthma of about 3%[6,7]. Nevertheless, studies aimed at the characterisation of radiological 
alterations of asthma have found bronchiectasis on chest high-resolution computed tomography 
(HRCT) in 17-35% of asthma patients[33–36]. These alterations have been associated more 
frequently with cases of non-allergic asthma and more severe forms of the disease[34,35]. 
However, a study performed by Menzies et al. also found a 2.01 increased hazard ratio of 
bronchiectasis among asthma patients with sensitization to Aspergillus fumigatus not meeting the 
diagnostic criteria for ABPA [36]. 
Unlike other aetiologies, morphological alterations of patients with asthma may affect all 
lung lobes, and both proximal and distal zones[37]. Finally, in a recent population study in the 
UK, the diagnosis of asthma was again found to be associated with a large number of patients 
with bronchiectasis, namely 42.5% [25]. It is difficult to define in which cases is bronchiectasis 
secondary to asthma and not the primary disease. Therefore, further studies are needed to better 
characterise this relationship and determine the impact on the prognosis of both diseases. 
 
2.5 Allergic bronchopulmonary aspergillosis (ABPA) 
This is a lung disease that occurs as a result of a hypersensitivity reaction to bronchial 
colonization by Aspergillus fumigatus[38]. The diagnosis of ABPA is performed using clinical 
and immunological criteria which are summarized in Table 3 [38]. The percentage of 
bronchiectasis associated with ABPA varies depending on the population analysed, from 1% in a 
study conducted in the US[18] to 7-8% in studies in the United Kingdom[5–7]. In some cases, it 
is difficult to make the diagnosis of ABPA because the result of serology tests such as total IgE 
and IgE specific to Aspergillus fumigatus can be similar to that observed in bronchial 
asthma[39]. Moreover, it is possible that the patient is in a stable phase at the time of the study 
and that structural damage occurred years before and that specific tests may give results that are 
normal or near normal[2]. In these cases, the identification of central bronchiectasis along with 
predominant impact on the upper lung lobes in chest HRCT can support the diagnosis of 
ABPA[40]. Chronic isolation of Staphylococcus aureus in bronchiectasis patients could also 
suggest ABPA as an aetiology, as this association has been reported in a previous study from 
Shah et al [41]. Its routine screening is recommended, since the identification of this disease 
implies specific management[2]. 
 
 
 
 
 
 
Table 3. Criteria used by the American Academy of Allergy, Asthma, and Immunology 
(AAAAI) for the diagnosis of allergic bronchopulmonary aspergillosis  
 
ABPA diagnostic criteria 
Minimum criteria 
● Asthma or CF with impaired lung function 
● Immediate skin reaction to the Aspergillus antigen  
● Total serum IgE of 1000ng/ml (416 iu/ml) or greater 
● High levels of specific IgG and IgE for Aspergillus in serum 
● Pulmonary infiltrates on chest radiograph 
 
Additional criteria 
● Peripheral blood eosinophilia  
● Presence of precipitating antibodies for Aspergillus in serum 
● Central bronchiectasis 
● Isolation of Aspergillus in mucus plugs 
 
Classified as ABPA-CB or ABPA-S (seropositive) according to the presence or 
absence of central bronchiectasis, respectively. 
 
 
CF: Cystic fibrosis; Ig: Immunoglobulin; ABPA: allergic bronchopulmonary aspergillosis 
 
2.6 Connective tissue diseases 
Bronchiectasis have been associated with multiple systemic diseases and connective 
tissue disease is thought to be the cause in up to 10-16% of patients in studies in Europe and the 
US[7,18]. Among the more notable are connective tissue diseases such as rheumatoid arthritis 
(RA) and Sjögren's syndrome, although bronchiectasis has been identified in patients with 
systemic sclerosis, systemic lupus erythematosus, ankylosing spondylitis, relapsing 
polychondritis, Marfan syndrome and Ehlers Danlos syndrome[42]. The association of 
bronchiectasis with RA is the most studied among these systemic diseases. An incidence of 
bronchiectasis of approximately 5% in patients with RA and respiratory symptoms has been 
reported, which is higher than the incidence of pulmonary fibrosis in those patients[43]. Like 
other pleuropulmonary manifestations of RA, bronchiectasis precedes articular manifestations in 
a large number of patients. This supports the hypothesis that chronic bronchial infection could be 
one of the triggers of RA[44]. Remy-Jardin et al. observed that approximately 30% of patients 
with RA who underwent chest HRCT had bronchiectasis. Although this finding was more 
frequent in patients with respiratory symptoms, about 8% of patients were asymptomatic[45]. A 
recent study by Perry et al. found that patients with RA and bronchiectasis present higher activity 
and severity of the disease and higher levels of anti-citullinated peptide antibodies when 
compared with patients with RA only[46]. 
Other collagenopathies have been much less studied. Studies aimed at characterizing the 
radiological changes of the lung by chest HRCT in patients with systemic sclerosis and systemic 
lupus erythematosus identified bronchiectasis in 59% and 21% respectively[47,48]. More studies 
are needed to elucidate the pathogenesis of the association between bronchiectasis and these 
diseases, as well as to determine the clinical impact that these bronchial abnormalities have on 
the course of the different systemic diseases. 
It has been reported that connective tissue disease and in particular RA associated 
bronchiectasis is associated with a poorer prognosis, requiring more intensive monitoring. 
Whether this reflects the nature of the disease or the impact of the immunosuppressive drugs 
frequently used to treat RA is unclear[49].  
 
2.7 Inflammatory bowel disease (IBD) 
Bronchiectasis are the most common pulmonary manifestation of IBD[50]. They have 
been associated with IBD in approximately 1-3% depending on the population studied[4–7,18]. 
Among these, ulcerative colitis has the most clearly established relationship, but an association 
has also been suggested with Crohn's disease [42]. The most common form of presentation is the 
appearance of coughing with chronic bronchorrhea in patients with IBD, many after being 
colectomised[51]. One of the proposed theories suggests that this is because inflammatory 
mediators change from the resected intestine to the lung due to their common embryological 
origin[52]. In some cases, treatment with inhaled and oral glucocorticosteroids has been 
effective, including their instillation via bronchoalveolar lavage[42], but there is insufficient 
evidence to prescribe this treatment routinely[1,2]. 
 
2.8 Ciliary dysfunction 
Primary ciliary dyskinesia (PCD) is a rare aetiology characterised by early onset. It is a 
hereditary transmitted disease and about 30 associated genes have been isolated, which can 
determine the heterogeneity and severity of the presentation between individuals[53,54]. It 
usually appears in childhood in the form of neonatal respiratory distress syndrome, chronic 
cough and/or chronic nasal congestion in more than 80% of cases[54]. Other frequent findings 
include chronic rhinosinusitis, dextrocardia, chronic otitis media, hearing loss, anosmia, 
infertility and diffuse bronchiectasis.  
In screening patients with suspected PCD, the saccharin test has many limitations on the 
undergoing and interpretation of results, so new techniques have been studied to improve the 
diagnosis of this condition [53]. Nasal nitric oxide (nNO) levels are usually low in PCD patients 
(around 10-20% of normal values) [53,55]. Therefore, its use as a diagnostic test has grown as 
more specialized centres have standardized protocols and availability for this technique [53]. 
Measuring nNO levels has been proven useful in the diagnosis of PCD in adults and children 
over 5 years of age, but since the technique requires patients to perform trained velum closure or 
to exhale against resistance (in order to limit contamination with air from lower airways), 
reproducibility is limited in younger children [55]. However, low nNO levels can also be found 
in CF, acute upper airways infections, sinusitis and nasal polyposis, so it should not be used as 
single diagnostic test [56]. The gold standard for diagnosis is electron microscopy, although it is 
recommended that the workup be conducted combining various tests such as the frequency and 
pattern of ciliary beating and the determination of nNO to support the diagnosis [57]. Currently 
there is no specific treatment for PCD, and few data is available to support strong 
recommendations on the management of patients with this disease. Nevertheless, the European 
Respiratory Society task force recommends that patients with PCD should be evaluated and 
closely followed in centres specializing in this disease by a multidisciplinary team, including 
education in airway clearance techniques, based on CF guidelines [58]. 
 
2.9 Alpha-1-antitrypsin (AAT) deficiency 
The association between AAT deficiency and bronchiectasis remains controversial. The 
prevalence of bronchiectasis in patients with AAT deficiency varies greatly between studies, 
probably because other aetiologies were not studied in many of them[59,60]. Screening of AAT 
deficiency is not recommended in the study of bronchiectasis, except in cases in which 
emphysema on chest HRCT is identified, particularly in a panlobular or basal distribution[2]. 
Although specific treatment for AAT deficiency is available and it is likely to improve the 
natural history of bronchiectasis, more evidence is needed to prove its benefit on these patients.  
 
2.10 Gastrointestinal aspiration 
The aspiration of gastrointestinal contents have been reported as the cause of 
bronchiectasis in some studies[4–7,18]. Although few studies exist which aim to analyse this 
relationship, Lee and colleagues found a prevalence of gastroesophageal reflux (GER) in 40% of 
patients with bronchiectasis[61]. In the same vein, a recent study by McDonnell et al. observed a 
high prevalence of hiatus hernia and GER symptoms in individuals with bronchiectasis in stable 
phase[62]. The presence of GER has been also associated with greater severity of bronchiectasis 
and a worse outcome of the disease[7,62]. Whether GER is a common cause of bronchiectasis or 
not it seems reasonable to treat GER where it is identified.  
 
2.11 Cystic fibrosis  
Although the majority of cystic fibrosis is diagnosed by neonatal screening or presents 
during childhood, we continue to identify some cases of CF presenting with apparently 
idiopathic bronchiectasis during adulthood. Features suggesting the need to exclude CF will 
include early age at presentation, the presence of non-respiratory features such as malabsorption 
or infertility, the early presence of Pseudomonas aeruginosa, Burkholderia cepacia or 
Staphylococcus aureus and the presence of an upper lobe distribution on CT. Whether 
heterozygosity for CFTR mutations contribute to the development of bronchiectasis is unclear. 
Investigation is with sweat test and genetic screening.  
 
2.12 Idiopathic causes 
This category encompasses all patients with bronchiectasis in whom it was not possible 
to identify a cause despite a full aetiological study. The prevalence of this group varies greatly 
depending on the population and the rigour of the diagnostic study, and lies between 26-74%[6]. 
A sub-analysis by Shoemark et al. reported an older mean age at diagnosis and predominant 
involvement of lower lobes in individuals with idiopathic bronchiectasis compared with patients 
with post infectious bronchiectasis, who had a mean age at diagnosis of 7 years and more diffuse 
lung involvement[5]. Lonni and colleagues also noted that the group of patients without a 
definite cause had more mild to moderate bronchiectasis compared to the other subjects[7]. 
Despite these findings, it is still a very heterogeneous group and more studies are needed to 
understand and identify the causative mechanisms of bronchiectasis in these patients. 
 
4. APPROACHES TO AETIOLOGICAL DIAGNOSIS 
Bronchiectasis may be related to many diseases and many of them may require specific 
treatment. Identifying the cause of this bronchial disease may determine patient management or 
the need for genetic testing of individuals and their relatives in 7-13% of cases[6,7]. Therefore, it 
is recommended to try determining the diagnosis of the cause of bronchiectasis in all cases where 
possible. 
Some aetiologies must be ruled out in all patients with bronchiectasis due to clinical 
implications in the management and prognosis. These include immunodeficiencies with antibody 
production deficiency, ABPA, primary ciliary dyskinesia, gastroesophageal reflux disease, 
mycobacterial infection, alpha-1 antitrypsin deficiency and CF[1]. Figure 1 summarises the 
proposed algorithm for addressing the aetiologic diagnosis[1,2]. 
 
 
Figure 1. Proposed algorithm for establishing the aetiologic diagnosis of bronchiectasis 
 
HRCT: high-resolution computed tomography; Ig: Immunoglobulin; Alpha-1-AT: Alpha-1 antitrypsin; ANA: 
antinuclear antibodies; ANCA: anti neutrophil cytoplasmic antibodies; RF: rheumatoid factor; ABPA: allergic 
bronchopulmonary aspergillosis; PCD: Primary ciliary dyskinesia; FENO: Fraction of exhaled nitric oxide, COPD, 
Chronic obstructive pulmonary disease. 
 In summary, all bronchiectasis patients should undergo a detailed medical background 
assessment and at least a basic study of immunoglobulin levels. If no immunodeficiency is 
detected, specific tests must be performed according to clinical history. The diagnosis of 
postinfectious bronchiectasis is made when other aetiologies have been ruled out and a history of 
severe respiratory infections exists. Finally, idiopathic bronchiectasis can be diagnosed only after 
a negative thorough aetiological study and no other bronchiectasis-related comorbidities are 
identified.  
 
CONCLUSIONS 
Identifying the aetiology of bronchiectasis is challenging, but important as early identification of 
treatable underlying disorders can lead to a change in management. We advocate a systematic 
approach to investigation for every patient with careful exclusion of each of the underlying 
conditions listed above. Continued improvements in the investigation and management of 
bronchiectasis will lead to better long term outcomes.  
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